• Home
  • Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).

Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT).

Author List
Dispenzieri A, Krishnan A, Arendt B, Blackwell B, Wallace PK, Dasari S, Vogl DT, Efebera Y, Fei M, Geller N, Giralt S, Hahn T, Howard A, Kohlhagen M, Landau H, Hari P, Pasquini MC, Qazilbash MH, McCarthy P, Shah N, Vesole DH, Stadtmauer E, Murray D
Publication
Blood cancer journal
Publication ID (Profile URL)
https://researcherprofiles.org/profile/263460348
Publication Year
2022
PubMed ID
35145071
Publication Title
Dispenzieri A, Krishnan A, Arendt B, Blackwell B, Wallace PK, Dasari S, Vogl DT, Efebera Y, Fei M, Geller N, Giralt S, Hahn T, Howard A, Kohlhagen M, Landau H, Hari P, Pasquini MC, Qazilbash MH, McCarthy P, Shah N, Vesole DH, Stadtmauer E, Murray D. Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). Blood Cancer J. 2022 02 10; 12(2):27.